cytic cells were demonstrated previously. However, the mechanism of those effects remained unclear. Here, we report on enhanced cytotoxicity of the lentiviral lytic peptide I (LLP-I) of gp41, the envelope transmembrane glycoprotein of HIV-1, in the presence of γ-GCE. Without γ-GCE, the cytotoxic effect of LLP-I was transient, whereas with γ-GCE, cell death induced by LLP-I remained continuous until termination. Of note, such effects by γ-GCE were also observed with another unrelated amphipathic peptide toxin, melittin. These results suggest that the synergistic cytotoxic effect of γ-GCE and LLP-I may play a central role in the molecular mechanism of the selective cytotoxicity of γ-GCE in HIV-1-infected T lymphocytic cells.
Over the past few years, a variety of antioxidative agents have been evaluated for their potential effects against human immunodeficiency virus type 1 (HIV-1). Such antioxidants, including D-penicillamine, 2,3-dimercapto-1-propanol, N-acetyl cysteine (NAC) and other glutathione (GSH) precursors, have been shown to inhibit HIV-1 gene expression from the long terminal repeat (LTR) (Chandra et al., 1988; Kubota et al., 1990; Roederer et al., 1990 Roederer et al., , 1992 Kalebic et al., 1991) . It has been reported that reduced GSH levels are frequently found in HIV-1-infected individuals (Eck et al., 1989; Buhl et al., 1989; Staal et al., 1992; Aukrust et al., 1995; Cayota et al., 1996) . This gave us a firm rationale for further investigation of GSH and its prodrugs for application in AIDS prevention and therapy. As such, most later studies have been focused on GSH prodrugs, especially NAC, and have shown their clear effect against cytokine-stimulated HIV-1 gene expression from latent proviruses, despite a controversial report describing an enhancement of HIV-1 growth by NAC in peripheral blood mononuclear cells (PBMCs) in direct contact with U1 latently-infected monocytic cells (Chen et al., 1997) . However, it may be a critical weakness of these anti-HIV-1 agents that most of the GSH prodrugs lack a property to counteract active HIV-1 replication, which is continuously maintained in lymphoreticular tissues of HIV-1-infected-individuals in a variety of clinical stages (Embretson et al., 1993; Pantaleo et al., 1993; Ho et al., 1995; Wei et al., 1995; Huynen & Neuman, 1996) .
Recently, a unique GSH prodrug, γ-glutamylcysteine ethyl ester (γ-GCE) (Takimoto-Kamimura et al., 1990) , which had been originally described to be effective against heart and liver re-perfusion injury (Nishinaka et al., 1991; Kobayashi et al., 1992; Hoshida et al., 1994; Nakamura et al., 1994) , asthma (Ikuta et al., 1992) and cataracts (Ohtsu et al., 1991) , was found to possess novel anti-HIV-1 properties that might overcome such a weakness in other related compounds (Kubota et al., 1998) . As well as inhibiting HIV-1 replication in T cell lines and PBMCs, surprisingly, γ-GCE also selectively destroyed HIV-1-producing H-9 T lymphocytic cells and inactivated HIV-1 virions themselves. The same concentrations of γ-GCE did not affect the cell growth and viability of uninfected H-9 cells. Such anti-HIV-1 properties of γ-GCE also provided an efficient blockade for the acquisition of acute HIV-1 infection in H-9 cells. However, the mechanisms of those effects, which seem to mimic specific immunoclearance in vivo, have remained unknown.
Focusing on viral factors on the surface of both infected cells and viral particles, we identified a viral moiety that Introduction acts in synergy with γ-GCE in killing T lymphocytic cells. This moiety is the lentiviral lytic peptide I (LLP-I) of the HIV-1 envelope transmembrane glycoprotein, gp41. LLP-I had been predicted and directly shown to form a typical amphipathic α-helical structure, the interaction of which with a lipid bilayer causes pore formation on biomembranes and enhanced membrane permeability (Venable et al., 1989; Srinivas et al., 1992; Miller et al., 1993; Chernomordik et al., 1994) . As such, it is widely recognized that LLP-I itself is cytotoxic by cytolytic effects based on the above-mentioned amphipathic structure. A structural alteration was also confirmed on the surface of the HIV-1 virion itself, which alters the permeability of the viral envelope and enables efficient incorporation of exogenous molecules, such as deoxyribonucleosides (dNTPs), into virions (Zhang et al., 1996a) . The altered envelope structure provides a fundamental basis for natural endogenous reverse transcription (NERT), one of the critical steps in the life-cycle of HIV-1 (Zhang et al., 1996b) . Here, we describe novel cooperative cytotoxic effects of γ-GCE and LLP-I, which define gp41 as a central viral co-factor in the novel anti-HIV-1 actions of γ-GCE. Furthermore, a theoretical basis for the molecular mechanism of this synergistic effect was obtained through similar experiments, utilizing an unrelated amphipathic peptide.
Materials and Methods

Cells
The human T lymphoid cell line H-9 and H-9 cells chronically infected with an HIV-1 strain, HIV-1 IIIB (H-9/IIIB) (Popovic et al., 1984) were maintained in RPMI-1640 tissue culture medium supplemented with 10% foetal bovine serum (FBS) at 37°C.
Chemistry
The compound γ-GCE (TEI-2306) was synthesized, purified and provided by the Teijin Institute for Biomedical Research. Structural analyses had been performed and the results were described in a previous report (Takimoto-Kamimura et al., 1990) . Biological properties as GSH prodrugs were also described in several previous studies (Nishinaka et al., 1991; Kubota et al., 1998) . The synthetic peptide of LLP-I in HIV-1 gp41 was synthesized under F-MOC protocols, as described previously (Miller et al., 1993; Zhang et al., 1996a) . The peptide sequence of the synthetic LLP-I is NH 2 -Arg-Val-Ile-Glu-Val-Leu-Gln-Ala-Ala-Tyr-Arg-Ala-Ile-Arg-His-Ile-Pro-Arg-Arg-Ile-Arg-Gln-Gly-Leu-Glu-Arg-Ile-Leu-COOH, as illustrated in Figure 3 . The other amphipathic peptide toxin, melittin, is commercially available (Sigma).
Cytotoxicity assays
The selective cytotoxicity of γ-GCE against HIV-1-infected cells was evaluated by comparing the cytotoxicity on uninfected H-9 and H-9/IIIB cells. Evaluation of cytotoxicity was performed as described previously (Kubota et al., 1998) . Briefly, after being treated with a variety of concentrations of γ-GCE for six days, viable cell numbers were quantified by the trypan blue exclusion method. The synergistic cytotoxic effects of γ-GCE and amphipathic peptides were analysed, using uninfected H-9 cell cultures. The cells were seeded at a density of 2×10 5 /ml in growth medium, in the presence or absence of a variety of concentrations of either amphipathic synthetic peptides (LLP-I or melittin), with or without 1.25 mM of γ-GCE. The fixed dose for γ-GCE (1.25 mM) had been determined in our initial study (Kubota et al., 1998) to be appropriate for the present research. Each day after the beginning of the treatment, cell growth and viability were monitored by the trypan blue exclusion method.
Results
Dose-dependent selective toxicity of γ-GCE on H-9/IIIB cells The selective cytotoxicity of γ-GCE, which inhibits replication and propagation of HIV-1, has been described previously (Kubota et al., 1998) . Such an effect on HIV-1-infected T lymphocytic cells was confirmed herein, and found to be dose-dependent. In certain of these experiments, the human T lymphocytic cell line H-9 with (H-9/IIIB) (Popovic et al., 1984) or without chronic HIV-1 infection, was utilized. Six days of treatment with a variety of concentrations of γ-GCE clearly demonstrated that H-9/IIIB cells were sensitive to less than 1 mM of γ-GCE, whereas the growth of uninfected H-9 cells was not at all affected by 2.5 mM of γ-GCE ( Figure 1 ). These results are consistent with the former findings that showed the selectivity of γ-GCE to be 12.5-fold (Kubota et al., 1998) . Also, the results of dose-escalating experiments of γ-GCE treatment clearly indicated dose dependency of this selective cytotoxicity of γ-GCE on H-9/IIIB cells (Figure 1b ).
Enhanced and prolonged cytopathicity of LLP-I with co-existing γ-GCE Next, in exploring the mechanism(s) of such effects, we hypothesized that a particular specific viral factor could be cooperating with γ-GCE in exerting selective cytotoxicity. Since γ-GCE is supplied exogenously through the plasma membrane, as an initial step, we examined a possible interaction of a viral moiety that resides on the plasma membrane with γ-GCE in impairing the growth and viability of T lymphocytic cells. The major viral factors in contact with the plasma membrane of a virus-producing cell are the env The helical wheel diagram shown in the upper portion represents the amphipathic helix of LLP-I (HIV-1 strain: HXB2R) (Miller et al., 1993) . Charged residues are shown as white single letter codes in solid circle backgrounds, hydrophobic residues are represented by black single letter codes in open squares. The first and last residues included in this structure are marked with numbers 1 and 28, respectively. In the lower portion of the figure, the primary structure of melittin, which comprises hydrophobic and hydrophilic portions at the N and C termini, respectively, is shown in single letter codes. Hydrophobic and hydrophilic sides of both peptides are also indicated by oval shadings.
gene products. Among them, a small portion of the 41 kDa transmembrane glycoprotein, gp41, which had been entitled LLP-I, was chosen for evaluation, because of its cytolytic properties. Of note, in concordance with our previous data showing similar inactivating effects of γ-GCE on both HIV-1-infected cells and virions themselves, the membrane-permeabilizing effect of LLP-I had been reported on both cellular and viral surfaces (Venable et al., 1989; Srinivas et al., 1992; Miller et al., 1993; Chernomordik et al., 1994; Zhang et al., 1996a) . It has been widely recognized that an exogenous LLP-I peptide also causes the same membrane alteration, as demonstrated by 'internal' LLP-I within the viral envelope glycoprotein (Zhang et al., 1996a) . As such, synergistic effects of γ-GCE and exogenously added LLP-I peptide, in altering the viability and cell growth of H-9 cells, were suspected and investigated. Initially, uninfected H-9 cells were treated with a variety of concentrations of a synthetic LLP-I peptide (Miller et al., 1993) , in order to determine an adequate dose with which to examine additive effects of γ-GCE on the cytopathicity of LLP-I. The results are summarized in Figure  2a . Cytopathic effects were not clearly observed at concentrations as high as 8 µM, whereas 16 µM of LLP-I caused total cell lysis within 24 h. As a result of a series of experiments, 12 µM was determined to be the cytotoxic concentration that gave rise to 50% viability, as evaluated by 3 days of treatment, and was chosen for subsequent experiments. Under such conditions, the additive effect of γ-GCE on the cytotoxicity of LLP-I can be efficiently evaluated, to determine whether it is agonistic or antagonistic. The dose of γ-GCE was fixed at a previously described 'safe and effective' concentration, 1.25 mM, which had been shown to be high enough to block HIV-1 production in H-9/IIIB cells by the selective cytotoxity, and low enough not to affect the growth and viability of uninfected H-9 cells (Kubota et al., 1998) . Thus, the effects of γ-GCE on the cell growth and viability of H-9 cells were comparatively analysed in the absence or presence of 12 µM of LLP-I. As described previously and in Figure 1 of this report, 1.25 mM of γ-GCE alone did not impair the growth of H-9 cells. However, when γ-GCE was introduced with LLP-I, the cytopathic effects of LLP-I were drastically altered. As illustrated in Figure 2 , LLP-I alone did reveal remarkable cytotoxicity after 24 h of treatment, but afterwards, surviving cells recovered to start proliferation again, until the end of the experiments. In fact, the viability of the LLP-I-treated cells were markedly recovered to over 70% by day 3. In contrast, in the co-presence of γ-GCE, no such cellular recovery could be observed, with a slight enhancement of the initial cytopathic effect on day 1. Under these conditions, both cell numbers and viability continuously decreased until the complete ablation of the entire cell population occurred after day 2. Similar experiments with lower LLP-I concentrations also showed significant enhancement of the LLP-I cytotoxicity by γ-GCE, although the effects were not as distinct (data not shown). Therefore, it was clearly shown that γ-GCE exerts a dramatic synergistic effect on the cytopathicity of LLP-I. Melittin, another amphipathic peptide, has synergistic cytotoxicity with γ-GCE that is similar to LLP-I
The structural basis of the cytotoxicity of LLP-I has been well-investigated and described in a number of reports (Venable et al., 1989; Srinivas et al., 1993; Miller et al., 1993; Chernomordik et al., 1994) . It is widely recognized that LLP-I forms a typical amphipathic α-helix, which comprises both highly hydrophobic and hydrophilic portions in one molecule, to enable the direct attachment and pore formation on the lipid bilayer of biomembranes (Figure 3) . Similar structures can be found in a variety of cytolytic peptide toxins, such as magainin II (Zhang et al., 1996a) . Melittin (purchased from Sigma), which is the major toxin in bee venom, possesses another type of amphipathic structure. Unlike LLP-I, the amphipathicity of melittin is inscribed in the primary structure, rather than higherordered helical structure in LLP-I. As illustrated in Figure  3 , the N terminus of melittin includes a cluster of hydrophobic amino acid residues, whereas the C terminus is rich in charged and polar side chains. Such a primary structure itself confers amphipathicity, which causes cytolysis via interaction with the plasma membrane. In order to verify the role of amphipathicity in the synergistic effects of γ-GCE and LLP-I, it was evaluated to see if a cooperative cytotoxic effect with γ-GCE, as in the case of LLP-I, was observed utilizing this peptide toxin. Initially, an appropriate dose of melittin for the examination of the additive effect of another compound on its cytotoxicity was determined, similar to those studies performed with LLP-I. Consequently, a concentration of 1.6 µM was chosen for the evaluation of the effect of γ-GCE. Under the same conditions used with LLP-I, experiments were carried out with 1.6 µM of melittin instead of LLP-I, and a similar cytotoxicity profile was observed (Figure 4 ). This was namely cellular recovery from the initial damage by melittin after day 2, which was clear without γ-GCE, but was totally blocked by co-introduction of γ-GCE at a concentration of 1.25 mM. Enhancement of the initial cell damage on day 1 by γ-GCE was shown to be slightly stronger with melittin than with LLP-I, but this may simply represent the relatively weaker cytopathic effect of 1.6 µM of melittin, as compared to 12 µM of LLP-I, which might have also prolonged the death of treated cells until day 3. Apart from such subtle differences, the fact that similar results were obtained with both LLP-I and melittin strongly indicates that the amphipathicity of peptides is a key factor for exerting a synergistic cytotoxic effect with γ-GCE on H-9 cells.
Discussion
We have found that γ-GCE enhances and prolongs the cytotoxic effects of LLP-I of HIV-1 gp41, which is now indicated to be a central mechanism for γ-GCE to exert the selective cytotoxicity and direct inactivating effects on HIV-1-producing cells and virions. Since similar findings were observed with another amphipathic peptide, interaction of γ-GCE with such an amphipathic molecule as LLP-I may be the critical key to yield the synergistic cytotoxic effects. At the given concentrations, both amphipathic peptides exerted limited cytotoxicity in the absence of γ-GCE, where the cells began proliferating again between 24 and 48 h from the beginning of the treatment. The observed cellular recovery may have been enabled by the following cellular and chemical factors. Firstly, cells proliferating after peptide treatment may represent particular populations with higher resistance against the membrane-targeted cytotoxic effect of the peptides. Secondly, gradual consumption of the added peptide onto plasma membrane should cause decreases of effective peptide concentrations over time, which allow the populations which survived to proliferate. However, in the presence of γ-GCE, such cellular recovery was blocked with enhanced levels of cytotoxicity.
This interaction between γ-GCE and LLP-I can be either direct or indirect. Since LLP-I itself permeabilizes biomembranes, influx of γ-GCE into the cell might be simply increased, which may result in cytotoxicity at lower concentrations within a non-toxic range. If so, the prolonged cytotoxic effect may be caused mainly by the internalized γ-GCE. Also, direct molecular interactions of γ-GCE and LLP-I may take place on the membrane. The esterified structure of γ-GCE confers both hydrophobic and hydrophilic portions at the ends of the molecule, enabling improved incorporation into the cell through the membrane. In addition to such an effect, γ-GCE might directly interact with LLP-I on the membrane, which may alter the structure of the cell surface more drastically than LLP-I alone. As such, cytotoxicity can be directly enhanced, possibly by the synergistic membrane destructive effect, caused by the γ-GCE/LLP-I interactions. According to this model, the loss of cellular recovery in the co-presence of γ-GCE is thought to be the consequence of initial termination of all cell populations by the synergistic cytotoxicity. In order to dissect possible interactions of γ-GCE and LLP-I on the membrane, in vitro studies using artificial biomembranes should be useful. Setting up these detailed experimental systems is underway.
Modification of the viral envelope via LLP-I to increase its permeability plays one of the important roles in the lifecycle of HIV-1. The efficient natural, endogenous reverse transcription occurring inside of the virion prior to infection is a critical strategy for HIV-1 to maximize its infectivity (Zhang et al., 1996a,b) , which is enabled by the LLP-I-mediated and enhanced permeability of the viral γ-GCE and LLP-I Antiviral Chemistry & Chemotherapy 10:3 envelope. Also, a similar alteration of the plasma membrane of infected cells may be a part of the cytopathicity of HIV-1, which alters cells to a more fragile state. As such, LLP-I is one of the key viral factors to maintain the infectivity and cytopathogenicity of HIV-1. Here, differential utility of γ-GCE as an anti-HIV-1 agent can be considered. Firstly, as described in our previous study (Kubota et al., 1998) , γ-GCE may be able to combat HIV-1 infection, in place of a perturbed immune system, by eradicating HIV-1-producing cells selectively, and by inactivating virions directly. However, to exert those effects, γ-GCE in effective concentrations of approximately 1 mM should be maintained in vivo, which obviously requires further investigation to establish improved means of drug delivery and maintenance. Secondly, even a lower concentration that may not be sufficient for active eradication of HIV-1, might be able to guide HIV-1 to evolve towards a less virulent viral strain. Constant presence of γ-GCE can be a selective evolutional pressure for HIV-1 to sort LLP-Inegative viruses for further survival. Namely, in order to overcome the pressure of γ-GCE, viruses may 'protect' their envelopes only by modifying their transmembrane glycoproteins to non-amphipathic, since they are unable to modify the basic structure of the host cellular membrane. Such viruses, lacking LLPs to alter the cell membrane and viral envelope, may be of lower infectivity and cytopathogenicity, which could lead to prolonged survival of infected-individuals and attenuated transmission. As a first step to verify this hypothesis, long-term in vivo evolutionary studies in experimental animal model systems with γ-GCE would have to be carried out.
